BioAlliance Pharma
59, Boulevard du Général Valin
Paris
75015
France
Tel: 33-0-145-5876-00
Fax: 33-0-145-5808-81
Website: http://www.bioalliancepharma.com/
212 articles about BioAlliance Pharma
-
BioAlliance Pharma: Approval Of Onxeo’s Admission To Secondary Listing And Trading On NASDAQ OMX Copenhagen
7/24/2014
-
BioAlliance Pharma Announces The Launch Of Sitavig® In The United States By Its Partner Innocutis
7/21/2014
-
BioAlliance Pharma Strengthens Its Financial Resources With The Support Of Its Top Shareholder
7/18/2014
-
BioAlliance Pharma And TopoTarget A/S Shareholders Approve Proposed Cross-Border Merger To Create Onxeo
6/30/2014
-
BioAlliance Pharma Release: Execution Of A License Agreement With EMS For Sitavig® In Brazil
6/25/2014
-
BioAlliance Pharma Has Received Pre-Approval For The Secondary Listing Of The Shares Of The Merged Company On NASDAQ OMX Copenhagen
6/20/2014
-
BioAlliance Pharma, TopoTarget A/S To Merge, Combined Entity To Be Named Onxeo
5/22/2014
-
BioAlliance Pharma: Livatag® Receives Fast Track Designation From The FDA For The Treatment Of Primary Liver Cancer
5/20/2014
-
BioAlliance Pharma SA: Quarterly Information As Of March 31, 2014
5/1/2014
-
BioAlliance Pharma Release: Quarterly Information As Of March 31, 2014
4/30/2014
-
Healthcap IV Is Committed To Vote In Support Of TopoTarget A/S’s Proposed Merger With BioAlliance Pharma
4/29/2014
-
BioAlliance Pharma And TopoTarget A/S To Merge To Form Orphan Oncology Powerhouse
4/16/2014
-
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase III Clinical Trial With Livatag® In Primary Liver Cancer
4/14/2014
-
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer
4/14/2014
-
BioAlliance Pharma Signs A New Licensing Agreement With Daewoong Pharmaceutical Co., Ltd. For Sitavig®’S Commercialization In South Korea
4/2/2014
-
BioAlliance Pharma Provides An Update On Its Partnerships For Loramyc®/Oravig®
4/1/2014
-
BioAlliance Pharma Collaborates With Penn Pharmaceutical Services On The Industrial Development Of Validive®
3/31/2014
-
BioAlliance Pharma Sitavig® Licensing Strategy Execution Of Licensing Agreement With Innocutis For North America
3/19/2014
-
BioAlliance Pharma Provides Updates On Its Major Achievements And Reports 2013 Consolidated Financial Results
2/27/2014
-
BioAlliance Pharma Provides Updates On Its Major Achievements And Reports 2013 Consolidated Financial Results
2/27/2014